Liver Disease News and Research RSS Feed - Liver Disease News and Research

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.
New tool can help doctors identify patients at highest risk for respiratory failure after surgery

New tool can help doctors identify patients at highest risk for respiratory failure after surgery

A new prediction tool can help doctors better identify patients who are at highest risk for respiratory failure after surgery and therefore prevent the often deadly condition, suggest data from a large multi-center study published in the May issue of Anesthesiology. [More]

Cost of Hep C medicines vexing insurers

As health insurance companies reveal much anticipated first-quarter earnings, it's the unpredictable impact from the five-figure cost of new Hepatitis C treatments that are the subject of as much Wall Street worry as the Affordable Care Act. [More]

Skin docs prescribe costlier drugs after free samples

In other news, panels recommend a costly hepatitis C drug for the sickest patients, and cancer doctors will compare the value of costly cancer drugs. [More]

First Edition: April 17, 2014

Today's headlines include reports about emerging political strategies related to the health law and the upcoming congressional elections. [More]

Allergist says people allergic to multiple trees may have tough allergy this spring

The polar vortex may be on its way out, but it's certainly leaving its footprints behind. As spring rolls in, people allergic to multiple trees may have a tough allergy season - a consequence of the cold winter, says Mark Dykewicz, M.D., professor of allergy and immunology at Saint Louis University. [More]
Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long. [More]

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). [More]
New data focuses on different approaches to improve diagnosis and treatment of HCC

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). [More]

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle. [More]

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. [More]

High cost of potent hepatitis drug presents challenges across the U.S.

Sovaldi, the hepatitis C treatment drug, is considered a breakthrough for patients with the disease. However, since, it won federal approval in December, lawmakers, insurers and patient advocates have begun an all-out revolt over it's high price point of $1,000 a daily pill or $84,000 over 12 weeks of treatment. [More]

New data shows that gut microbiota has potential role in development of ALD

Exciting new data presented today at the International Liver Congress- 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD). [More]
Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute. [More]

Scientists uncover mechanism and possible treatment to reverse immune suppression in liver disease patients

The mechanism which underlies the susceptibility of liver disease patients to life-threatening infection has been uncovered by Wellcome Trust-funded medical scientists, who have also suggested a possible treatment to reverse immune suppression in these patients. [More]
UK study finds link between low vitamin D status and non-alcoholic fatty liver disease in British children

UK study finds link between low vitamin D status and non-alcoholic fatty liver disease in British children

A UK study investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity. [More]

S. pneumoniae serotypes differ between primary and post-viral disease

Certain capsular serotypes of Streptococcus pneumoniae are particularly likely to cause disease in people who have recently experienced a respiratory viral infection, study findings indicate. [More]

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy. [More]

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV). [More]

Study shows impact of hepatic encephalopathy on liver disease patients

New data presented today at the International Liver Congress show the impact of hepatic encephalopathy on liver disease patients and healthcare systems. [More]

Viral hepatitis linked to more deaths than HIV across EU countries

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014. [More]